Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for MGC026 in Cancer, Solid tumor/s. The expected timing is based on the latest available company guidance and may change.
5/9/24 Ph1 dose escalation study ongoing. 5/13/25- Dose expansion in selected indications expected to initiate in 2025. 11/12/25:- Ph1 dose escalation completed and two solid tumor dose expansion cohorts initiated; timing of Ph1 data readout has not yet been provided. 03/09/26:- Initial Ph1 MGC026 clinical data expected in Mid-2026. 05/13/26:- Company reiterates ongoing Ph1 dose expansion and expects initial MGC026 clinical data in Mid-2026. 07/23/26:- Interim Ph1 results to be presented at ESMO 2026 on October 23, 2026. 08/13/26:- Ph1 interim results were accepted for ESMO 2026 poster presentation on October 23, 2026. SCCHN cohort advanced to Stage 2.
Verification
Confirm timing and program details against the company announcement or filing.